Therefore, hypomethylation recovery of FER1L4, GAS5, and MEG3 may be a potential therapeutic target for RA (Liu et al., 2019; Yu et al., 2019; Li et al., 2020). The gene discussed is MEG3; the disease is rheumatoid arthritis.